Table 1.
Baseline Characteristics by Randomized Treatment Group
| Characteristic | Total (N = 234) | Atazanavir/Ritonavir (N = 68) | Raltegravir (N = 82) | Darunavir/Ritonavir (N = 84) |
|---|---|---|---|---|
| Demographics | ||||
| Sex, male | 210 (90%) | 63 (93%) | 73 (89%) | 74 (88%) |
| Age, y | 36 (28–45) | 38 (31–44) | 36 (27–45) | 36 (28–47) |
| Race/ethnicity | ||||
| White non-Hispanic | 112 (48%) | 35 (51%) | 36 (44%) | 41 (49%) |
| Black non-Hispanic | 68 (29%) | 21 (31%) | 23 (28%) | 24 (29%) |
| Hispanic, regardless of race | 45 (19%) | 11 (16%) | 16 (20%) | 18 (21%) |
| Medium/High 10-year risk of hard coronary heart disease, % (≥6%)a | 29 (12%) | 7 (10%) | 7 (9%) | 15 (18%) |
| Human immunodeficiency virus type 1 RNA, log10 copies/mL | 4.6 (4.0–5.0) | 4.8 (4.0–5.2) | 4.5 (4.0–4.9) | 4.6 (4.0–5.0) |
| CD4+ cell count, cells/mm³ | 338 (191–448) | 294 (180–461) | 347 (246–450) | 337 (172–424) |
| CD8+ cell count, cells/mm³ | 823 (578–1089) | 823 (577–1055) | 884 (607–1086) | 764 (545–1118) |
| Body mass index, kg/m² | 25 (22, 28) | 26 (23, 29) | 25 (22, 28) | 24 (22, 27) |
| Current smoker | 77 (33%) | 22 (32%) | 28 (34%) | 27 (32%) |
| Biomarkers (available measures) | ||||
| High-sensitivity C-reactive protein, μg/mL (n = 231) | 1.5 (0.8–3.2) | 1.8 (1.0–3.2) | 1.3 (0.7–3.4) | 1.3 (0.7–3.2) |
| IL-6, pg/mL (n = 231) | 1.7 (1.2–2.8) | 1.9 (1.2–2.9) | 1.5 (1.0–2.8) | 1.7 (1.3–2.8) |
| D-dimer, μg/mL (n = 232) | 0.3 (0.1–0.6) | 0.3 (0.1–0.5) | 0.3 (0.1–0.5) | 0.3 (0.2–0.6) |
| GlycA, μmol/L (n = 230) | 411 (366–451) | 420 (388–456) | 399 (363–446) | 408 (357–443) |
| %CD4+: CD38+HLADR+ (n = 212) | 18 (12–30) | 18 (12–28) | 19 (12–32) | 17 (10–30) |
| %CD8+: CD38+HLADR+ (n = 212) | 43 (34–54) | 40 (33–57) | 45 (37–52) | 43 (32–54) |
| sIL-2r, pg/mL (n = 232) | 1790 (1178–2310) | 1898 (1340–2291) | 1664 (1065–2435) | 1651 (1179–2242) |
| soluble CD14, ng/mL (n = 229) | 1688 (1454–2023) | 1799 (1486–2157) | 1663 (1438–1924) | 1646 (1451–2024) |
| soluble CD163, ng/mL (n = 217) | 1090 (773–1560) | 1144 (799–1550) | 1249 (898–1564) | 1012 (708–1548) |
| %MNC: CD14(dim)CD16+ (n = 212) | 62 (48–71) | 58 (46–65) | 62 (47–73) | 63 (54–72) |
| %MNC: CD14+CD16+ (n = 212) | 8 (6–13) | 10 (6–16) | 7 (4–13) | 8 (6–12) |
Median (first and third quartiles) or number (%).
Abbreviations: HLADR, human leukocyte antigen DR; IL, interleukin; MNC, monocyte.
a Hard indicates severe cardiovascular event.